biib115
Nucleic acidexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Oct 10, 2022 (NCT05575011)
Timeline
Indications
Mechanism of action
- SMN2 pre-mRNAANTISENSE INHIBITOR
SMN2 pre-mRNA antisense inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068460 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07221669 | Phase 3 | Jan 30, 2026 | Biogen |
| NCT05575011 | Phase 1 | Oct 10, 2022 | Biogen |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biogen | For profit | 2 | 2 | 2 | 2022 |
1 organizations
Page 1 / 1